Quantcast

Industry news that matters to you.  Learn more

The Michael J. Fox Foundation Funds Research to Develop Parkinson’s Blood Test

Research being performed by Durin Technologies, Inc., exploring the development of a novel blood test for Parkinson’s disease was recently awarded a second grant from The Michael J. Fox Foundation for Parkinson’s Research.

Inventages Portfolio Company, Cognoptix, Demonstrates the Ability to Accurately Identify Alzheimer’s Disease

Inventages announces that one of its portfolio companies, Cognoptix, has demonstrated unprecedented accuracy in detecting Alzheimer’s disease. A multi-site clinical trial of the SAPPHIRE II eye test showed a sensitivity of 85% and a specificity of 95% in differentiating Alzheimer’s disease patients from healthy volunteers.

Personalized Medicine Roadmap: Definiens Releases Five Steps to Utilize Data Mining with Image Analysis

Definiens, a healthcare company that advances personalized medicine through image analysis and digital pathology solutions, recently released tips for integrating data mining with image analysis. As pathologists, researchers and clinicians seek to advance personalized medicine through the development and prescription of targeted therapies, data generated through image analysis of digitized tissue sections is becoming essential to stratifying patients and providing personalized care.

Evidence-Guided Molecular Profiling Offers New Hope for Oncologists Managing Difficult-to-Treat Cancers

Caris Life Sciences recently announced data from two studies presented at the 2013 European Cancer Congress (ECC 2013), which demonstrate the potential of evidence-guided molecular profiling to improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) origins as well as rare tumors and cancers that have been refractory to treatment.

University of Cambridge, Genomics England Ltd., and Illumina Collaborate to Sequence 10,000 Whole Human Genomes for National Health Service Patients

University of Cambridge, Genomics England Ltd., and Illumina, Inc. (NASDAQ:ILMN) recently announced the start of a three-year project that will sequence 10,000 whole genomes of children and adults with rare genetic diseases. The project represents a pilot for Genomics England Ltd., which will provide 2,000 samples, and marks the beginning of the national endeavor to sequence 100,000 genomes in the UK National Health Service (NHS), announced recently by the Prime Minister, David Cameron.